Inhibitory effects of flavonoids on phosphodiesterase isozymes from guinea pig and their structure-activity relationships

Biochemical Pharmacology

Volumn 68, Issue 10, 2004, Pages 2087-2094

  Ko, Wun Chang ^a   Shih, Chwen Ming ^a   Lai, Ya Hsin ^a   Chen, Jun Hao ^a   Huang, Hui Lin ^a  

^a TAIPEI MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Flavonoids; Guinea pig; Heart; Lung; Phosphodiesterase isozymes; Structure activity relationships

Indexed keywords

4 (3 BUTOXY 4 METHOXYBENZYL) 2 IMIDAZOLIDINONE; APIGENIN; BIOCHANIN A; DIOSMETIN; ERIODICTYOL; FLAVONOID; GENISTEIN; HESPERETIN; ISOENZYME; LUTEOLIN 7 GLUCOSIDE; MILRINONE; MYRICETIN; PHOSPHODIESTERASE; PHOSPHODIESTERASE I; PHOSPHODIESTERASE III; PHOSPHODIESTERASE IV; PHOSPHODIESTERASE V; PRUNETIN; QUERCETIN; SPLEEN EXONUCLEASE; UNCLASSIFIED DRUG; VINPOCETINE; ZAPRINAST;

ARTICLE; CONTROLLED STUDY; DRUG INHIBITION; DRUG POTENCY; DRUG SELECTIVITY; ENZYME PURIFICATION; IC 50; NONHUMAN; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION;

3',5'-CYCLIC-GMP PHOSPHODIESTERASE; 3',5'-CYCLIC-NUCLEOTIDE PHOSPHODIESTERASE; ANIMALS; FLAVONOIDS; GUINEA PIGS; ISOENZYMES; PHOSPHODIESTERASE INHIBITORS; PHOSPHORIC DIESTER HYDROLASES; QUERCETIN; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 5144221343     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2004.06.030     Document Type: Article

References (46)

1. M.E. Lee, J. Markowitz, J.O. Lee, and H. Lee Crystal structure of phosphodiesterase 4D and inhibitor complex FEBS Lett. 530 2002 53 58
2. T.J. Torphy, and L.B. Cieslinski Characterization and selective inhibition of cyclic nucleotide phosphodiesterase isozymes in canine tracheal smooth muscle Mol. Pharmacol. 37 1990 206 214
3. Z. Kapui, P. Schaeffer, E.G. Mikus, E. Boronkay, J. Gyürky, and J.M. Herbert Experimental studies on guanosine 3′, 5′-cyclic monophosphate levels and airway responsiveness of the novel phosphodiesterase type 5 inhibitor SR 265579 in guinea-pigs Drug Res. 49 1999 685 693
4. J. De Boer, A.J. Philpott, R.G. van Amsterdam, M. Shahid, J. Zaagsma, and C.D. Nicholson Human bronchial cyclic nucleotide phosphodiesterase isoenzymes: biochemical and pharmacological analysis using selective inhibitors Br. J. Pharmacol. 106 1992 1028 1034
5. P.J. Silver, L.T. Hamel, M.H. Perrone, R.G. Bentley, C.R. Bushover, and D.B. Evans Differential pharmacologic sensitivity of cyclic nucleotide phosphodiesterase isozymes isolated from cardiac muscle, arterial and airway smooth muscle Eur. J. Pharmacol. 150 1988 85 94
6. D.C. Underwood, C.J. Kotzer, S. Bochnowicz, R.R. Osborn, M.A. Luttmann, and D.W.P. Hay Comparison of phosphodiesterase III, IV and dual III/IV inhibitors on bronchospasm and pulmonary eosinophil influx in guinea pigs J. Pharmacol. Exp. Ther. 270 1994 250 259
7. J. Kuhnau The flavonoids: a class of semi-essential food components: their role in human nutrition World Rev. Nut. Diet. 24 1976 117 191
8. Y. Chen, R. Zheng, Z. Jia, and Y. Ju Flavonoids as superoxide scavengers and antioxidants Free Radic. Biol. Med. 9 1990 19 21
9. M.L. Ferrandiz, and M.J. Alcaraz Anti-inflammatory activity and inhibition of arachidonic acid metabolism by flavonoids Agent Act 32 1991 283 288
10. L.G. Menon, R. Kuttan, and G. Kuttan Inhibition of lung metastasis in mice induced by B16F10 melanoma cells by polyphenolic compounds Cancer Lett. 95 1995 221 225
11. R. Edenhardder, I. von Petersdorff, and R. Rauscher Antimutagenic effects of flavonoids, chalcones and structurally related compounds on the activity of 2-amino-3-methylimidazo[4,5-f]quinoline (IQ) and heterocyclic amine mutagens from cooked food Mutat. Res. 287 1993 261 274
12. J. Duarte, F.P. Vizcaíno, P. Utrilla, J. Jiménez, J. Tamargo, and A. Zarzuelo Vasodilatory effects of flavonoids in rat aortic smooth muscle. Structure-activity relationships Gen Pharmacol. 24 1993 857 862
13. T. Hayashi, K. Sawa, M. Kawasaki, M. Arisawa, M. Shimizu, and N. Morita Inhibition of cow's milk xanthine oxidase by flavonoids J. Nat. Prod. 51 1988 345 348
14. P.C. Ferriola, V. Cody, and E. Middleton Jr. Protein kinase C inhibition by plant flavonoids. Kinetic mechanisms and structure-activity relationships Biochem. Pharmacol. 38 1989 1617 1624
15. U.R. Kuppusamy, and N.P. Das Effects of flavonoids on cyclic AMP phosphodiesterase and lipid mobilization in rat adipocytes Biochem. Pharmacol. 44 1992 1307 1315
16. W.C. Ko, M.C. Chen, S.H. Wang, Y.H. Lai, J.H. Chen, and C.N. Lin 3-O-Methylquercetin more selectively inhibits phosphodiesterase subtype 3 Planta Med. 69 2003 310 315
17. W.J. Thompson, and M.M. Appleman Multiple cyclic nucleotide phosphodiesterase activities from rat brain Biochemistry 10 1971 311 316
18. H.S. Ahn, W. Crim, M. Romano, E. Sybertz, and B. Pitts Effects of selective inhibitors on cyclic nucleotide phosphodiesterases of rabbit aorta Biochem. Pharmacol. 38 1989 3331 3339
19. P.F. Mery, C. Pavoine, F. Pecker, and R. Fischmeister Erythro-9-(2-hydroxy-3-nonyl)adenine inhibits cyclic GMP-stimulated phosphodiesterase in isolated cardiac myocytes Mol. Pharmacol. 48 1995 121 130
20. S.A. Harrison, D.H. Reifsnyder, B. Gallis, G.G. Cadd, and J.A. Beavo Isolation and characterization of bovine cardiac muscle cGMP-inhibited phosphodiesterase: a receptor for new cardiotonic drugs Mol. Pharmacol. 29 1986 506 514
21. H. Sheppard, G. Wiggan, and W.H. Tsien Structure-activity relationships for inhibitors of phosphodiesterase from erythrocytes and other tissues Adv. Cyclic Nucleotide Res. 1 1972 103 112
22. P.G. Gillespie, and J.A. Beavo Inhibition and stimulation of photoreceptor phosphodiesterases by dipyridamole and M&B 22,948 Mol. Pharmacol. 36 1989 773 781
23. W.C. Ko, P.Y. Liu, J.L. Chen, I.J. Leu, and C.M. Shih Relaxant effects of flavonoids in isolated guinea pig trachea and their structure-activity relationships Planta Med. 69 2003 1086 1090
24. P. Cos, M. Calomme, J.B. Sindambiwe, T.D. Bruyne, K. Cimanga, and L. Pieters Cytotoxicity and lipid peroxidation-inhibiting activity of flavonoids Planta Med. 67 2001 515 519
25. H.K. Kim, B.S. Cheon, Y.H. Kim, S.Y. Kim, and H.P. Kim Effects of naturally occurring flavonoids on nitric oxide production in the macrophage cell line RAW 264.7 and their structure-activity relationships Biochem. Pharmacol. 58 1999 759 765
26. T. Akiyama, J. Ishida, S. Nakagawa, H. Ogawara, S.I. Watanabe, and N. Itoh Genistein a specific inhibitor of tyrosine-specific protein kinase J. Biol. Chem. 262 1987 5592 5595
27. M.R. Nichols, and B.H. Morimoto Differential inhibition of multiple cAMP phosphodiesterase isozymes by isoflavones and tyrphostins Mol. Pharmacol. 57 2000 738 745
28. S.D. Rybalkin, C. Yan, K.E. Bornfeldt, and J.A. Beavo Cyclic GMP phosphodiesterases and regulation of smooth muscle function Circ. Res. 93 2003 280 291
29. M.A. Giembycz Phosphodiesterase 4 inhibitors and the treatment of asthma. Where are we now and where do we go from here? Drug 59 2000 193 212
30. T.J. Torphy Phosphodiesterase isozymes, molecular targets for novel antiasthma agents Am. J. Respir. Crit. Care Med. 157 1998 351 370
31. H. Masuoka, M. Ito, M. Sugioka, H. Kozeki, T. Konishi, and T. Tanaka Two isoforms of cGMP-inhibited cyclic nucleotide phosphodiesterases in human tissues distinguished by their responses to vesnarinone, a new cardiotonic agent Biochem. Biophys. Res. Commun. 190 1993 412 417
32. E. Moon, R. Lee, R. Near, L. Weintraub, S. Wolda, and A. Lerner Inhibition of PDE3B augments PDE4 inhibitor-induced apoptosis in a subset of patients with chronic lymphocytic leukemia Clin. Cancer Res. 8 2002 589 595
33. W.J. Thompson, G.A. Piazza, H. Li, L. Liu, J. Fetter, and B. Zhu Exisulind induction of apoptosis involves guanosine 3′,5′-cyclic monophosphate phosphodiesterase inhibition, protein kinase G activation, and attenuated beta-catenin Cancer Res. 60 2000 3338 3342
34. H.J. Thompson, C. Jiang, J. Lu, R.G. Mehta, G.A. Piazza, and N.S. Paranka Sulfone metabolite of sulindac inhibits mammary carcinogenesis Cancer Res. 57 1997 267 271
35. J.T. Lim, G.A. Piazza, E.K. Han, T.M. Delohery, H. Li, and T.S. Finn Sulindac derivatives inhibit growth and induce apoptosis in human prostate cancer cell lines Biochem. Pharmacol. 58 1999 1097 1107
36. H. Li, L. Liu, M.L. David, C.M. Whitehead, M. Chen, and J.R. Fetter Pro-apoptotic actions of exisulind and CP461 in SW480 colon tumor cells involve beta-catenin and cyclin D1 down-regulation Biochem. Pharmacol. 64 2002 1325 1336
37. H.H. Schneider, R. Schmiechen, M. Brezinski, and J. Seidler Stereospecific binding of the antidepressant rolipram to brain protein structures Eur. J. Pharmacol. 127 1986 105 115
38. W.H. Zhu, A. Majluf-Cruz, and G.A. Omburo Cyclic AMP-specific phosphodiesterase inhibitor rolipram and Ro 20-1724 promoted apoptosis in HL60 promyelocytic leukemic cells via cyclic AMP-independent mechanism Life Sci. 63 1998 265 274
39. D. Marko, K. Romanakis, H. Zankl, G. Furstenberger, B. Steinbauer, and G. Eisenbrand Induction of apoptosis by an inhibitor of cAMP-specific PDE in malignant murine carcinoma cells overexpressing PDE activity in comparison to their nonmalignant counterparts Cell Biochem. Biophys. 28 1998 75 101
40. D.H. Kim, and A. Lerner Type 4 cyclic adenosine monophosphate phosphodiesterase as a therapeutic target in chronic lymphocytic leukemia Blood 92 1998 2484 2494
41. B. Siegmund, J. Welsch, F. Loher, G. Meinhardt, B. Emmerich, and S. Endres Phosphodiesterase type 4 inhibitor suppresses expression of anti-apoptotic members of the Bcl-2 family in B-CLL cells and induces caspase-dependent apoptosis Leukemia 15 2001 1564 1571
42. A. Kazi, K.G. Daniel, D.M. Smith, N.B. Kumar, and Q.P. Dou Inhibition of the proteasome activity, a novel mechanism associated with the tumor cell apoptosis-inducing ability of genistein Biochem. Pharmacol. 66 2003 965 976
43. J.E. Karp, D.D. Ross, W. Yang, M.L. Tidwell, Y. Wei, and J. Greer Timed sequential therapy of acute leukemia with flavopiridol: in vitro model for a phase I clinical trial Clin. Cancer Res. 9 2003 307 315
44. M. Aklilu, H.L. Kindler, R.C. Donehower, S. Mani, and E.E. Vokes Phase II study of flavopiridol in patients with advanced colorectal cancer Ann. Oncol. 14 2003 1270 1273
45. A.M. Senderowicz, and E.A. Sausville Preclinical and clinical development of cyclin-dependent kinase modulators J. Natl. Cancer Inst. 92 2000 376 387
46. A.M. Senderowicz Small-molecule cyclin-dependent kinase modulators Oncogene 22 2003 6609 6620